Renowned luminaries in Personalized Medicine
Groundbreaking companies with emerging technologies
More than 1000 peers from around the globe
50 sessions in 3 parallel tracks

CO-HOSTED WITH
STANFORD HEALTH CARE, UCSF, & ORACLE

Commercial Applications in Liquid Biopsy

Liquid biopsy has captured the imagination of investors and the mainstream press alike.  While the ability to assess patients non-invasively is appealing to physicians and patients, there remains much confusion regarding the capabilities and limitations of various technologies.  This session will provide meaningful data and debate on the clinical utility of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and exosomes.  Companies representing each technology will present and answer audience questions regarding what some estimates forecast to be a $10BN diagnostic industry.

FEATURED SPEAKERS

Frederic Pla, Ph.D., Chief Business & Product Development Officer, Genomic Health

Over the last 25 years, Frederic Pla has built and launched global businesses in medical diagnostics and devices, life sciences, and healthcare information technology, consistently delivering high growth and profitability through a blend of product innovation, strategic acquisitions, and successful turnarounds.  Read Full Bio

Thomas Krahn, Ph.D., Head of Global Biomarker Research, Bayer Pharmaceuticals

Dr. Thomas Krahn is heading the department of Global Biomarker Research within Bayer Pharma AG. The main task of this department is translational research supporting early clinical trials by identification and qualification of specific biomarkers and evaluation of new technologies. Read Full Bio

Wolfgang Daum, Chairman and CEO, Toma Biosciences

Wolfgang is an executive and serial entrepreneur in healthcare (diagnostics, medical devices, and health services). Currently he serves as Chairman and CEO of TOMA Biosciences, Inc. a fast growing genomic cancer diagnostic company. Read Full Bio

George Karlin-Neumann, Ph.D., Director of Scientific Affairs, Bio-Rad

Dr. George Karlin-Neumann is a molecular geneticist, biotechnologist and entrepreneur. He co-founded ParAllele BioScience, a successful high throughput genomics company, out of the Stanford Genome Technology Center in 2001. Dr.Karlin-Neumann joined Affymetrix in 2005 after it acquired ParAllele for its highly multiplexed genetics and genomics assay technology. Read Full Bio

Nicholas Dracopoli, Ph.D., Vice President, Janssen R&D

Dr. Nicholas Dracopoli is Vice President, Head Oncology Biomarkers at Janssen R&D, Johnson & Johnson. In this role he is responsible for biomarker discovery, development and applications for oncology products. Previously, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb, and prior to that spent five years in the biotechnology industry at Sequana Therapeutics. Read Full Bio

Matthew Hill, Ph.D., Vice President, Research & Development, Natera

Dr. Hill is an expert in genetics, molecular biology, and bioinformatics. While in graduate school at Stanford, Dr. Hill constructed the first genetic map of a chordate model organism which led to important insights about the nature of genome evolution. Read Full Bio

Raghu Kalluri, M.D., Ph.D., Chairman & Professor, Dept. of Cancer Biology, MD Anderson

In 2015, Kalluri’s lab at MD Anderson received widespread attention for a discovery that could lead to a blood test that detects pancreatic cancer at an early stage, before it spreads to other organs and becomes too difficult to treat. Kalluri received his PhD in Biochemistry and Molecular Biology from the University of Kansas Medical Center. Read Full Bio

Katherine Richardson, Ph.D., Vice President, Research and Development, Transgenomic, Inc.

Dr. Richardson holds an SB degree in Life Sciences from the Massachusetts Institute of Technology and a PhD in Molecular Cellular and Developmental Biology from Iowa State University. Prior to joining Transgenomic, she worked for eight years as a scientist with OSI Pharmaceuticals, where she specialized in molecular biology research and development in the area of oncology. Read Full Bio

Walter Koch, Ph.D., Vice President & Head of Global Research, Roche Molecular Systems, Inc.

Dr. Koch has been in his current role of VP and Head of Global Research for Roche Molecular Systems since 2005. As a member of the Executive Leadership Team, he sits on the Life Cycle and Business Development committees, and chairs the Research Portfolio Committee. He is responsible for all RMD research and early development activities, including research efforts associated with biomarker discovery and validation. Read Full Bio

Victor E. Velculescu, M.D., Ph.D., Co-Director, Cancer Biology, Johns Hopkins Kimmel Cancer Center

Dr. Velculescu is Co-Director of Cancer Biology and Professor of Oncology and Pathology at the Johns Hopkins University Kimmel Cancer Center. His research interests are focused on genomic analyses of human cancer and using such information to understand the underlying biology of cancer and to identify new diagnostic and therapeutic approaches. Read Full Bio

Maximilian Diehn, M.D., Ph.D., Assistant Professor, Stanford University School of Medicine

Max Diehn MD, PhD is an Assistant Professor of Radiation Oncology at Stanford University. He has co-appointments in the Stanford Cancer Institute and Institute for Stem Cell Biology and Regenerative Medicine. Dr. Diehn trained at Harvard University and Stanford University and has a background in genomics and stem cell biology. Read Full Bio

David Spetzler, MBA, Ph.D., SVP & CSO, Caris Life Sciences

Dr. Spetzler joined the Caris scientific team in August of 2009, where he currently leads the Research and Development division of Caris. His executive and scientific oversight of the R&D team is focused on the development of clinical assays to aid in the creation of precision medicine strategies for individual cancer patients. Read Full Bio

Roopom Banerjee, President & CEO, RainDance Technologies

Roopom Banerjee is President and CEO of RainDance Technologies. Previously, he held positions at Leerink Swann, McKinsey & Company and Goldman Sachs advising Fortune 500 healthcare companies on corporate and growth strategies. He’s completed over 50 transactions, including IPOs, private placements and mergers and acquisitions. Read Full Bio

Paul Y. Song, M.D., Chief Medical Officer, Cynvenio

A respected clinician and seasoned medical executive with more than two decades of experience in the field of oncology, Dr. Song oversees Cynvenio’s translational and clinical research programs. Dr. Song is also a member of the faculty at Cedars Sinai Medical Center, in the Samuel Oschin Cancer Center department of radiation oncology and biomedical sciences. Read Full Bio

Murali Prahalad, Ph.D., President & CEO, Epic Sciences

Dr. Prahalad currently holds the title of President and CEO of Epic Sciences, Inc. (EPIC), a venture backed cancer management company specializing in the detection and analysis of circulating tumor cells (CTCs). Read Full Bio

Helmy Eltoukhy, Ph.D., CEO, Guardant Health

Helmy Eltoukhy, PhD, is a biotech pioneer with deep expertise in next-generation digital sequencing technologies and genetic analysis systems. He is currently the co-founder and CEO of Guardant Health, the market leader in liquid biopsies. Helmy’s prior startup, Avantome, was a leader in low-cost sequencing, before being acquired by Illumina. Read Full Bio

Mark Erlander, Ph.D., CSO, Trovagene

Mark Erlander has more than 18 years of experience directing and leading research and development for gene discovery, with a strong focus on molecular diagnostics. Since 2012, Dr. Erlander has also served as Chief Scientific Officer of Gensignia, Inc., a lung cancer diagnostics company. Read Full Bio

Phil Stephens, Ph.D., Chief Scientific Officer Foundation Medicine

Dr. Stephens joined Foundation Medicine in March 2011, bringing more than a decade of experience in cancer genomics to the company. Dr. Stephens is a world-renowned expert in next-generation sequencing and cancer genome analysis and has authored numerous publications in Nature, Nature Genetics, Nature Medicine, Cell and other high-profile journals. Read Full Bio

 
Web Analytics